• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    2/14/24 8:05:52 AM ET
    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email

    Gainers

    • Cogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. The company's market cap stands at $684.6 million.
    • Lineage Cell Therapeutics (AMEX:LCTX) stock rose 18.62% to $1.21. The company's market cap stands at $228.0 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) stock increased by 17.39% to $2.16. The market value of their outstanding shares is at $34.6 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares rose 16.71% to $0.65. The market value of their outstanding shares is at $22.2 million.
    • Allakos (NASDAQ:ALLK) shares increased by 15.74% to $1.47. The company's market cap stands at $128.5 million.
    • Cardiff Oncology (NASDAQ:CRDF) shares increased by 13.19% to $1.88. The company's market cap stands at $83.9 million.

    Losers

    • Anitra (AMEX:AZTR) stock declined by 67.8% to $0.28 during Wednesday's pre-market session. The company's market cap stands at $3.3 million.
    • QuidelOrtho (NASDAQ:QDEL) stock fell 39.35% to $40.5. The company's market cap stands at $2.7 billion. As per the press release, Q4 earnings came out yesterday.
    • Sonnet BioTherapeutics (NASDAQ:SONN) stock declined by 11.98% to $1.36. The company's market cap stands at $4.1 million.
    • Renalytix (NASDAQ:RNLX) shares fell 11.35% to $1.25. The company's market cap stands at $62.4 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock decreased by 10.56% to $1.61. The company's market cap stands at $4.2 million.
    • Biotricity (NASDAQ:BTCY) stock decreased by 10.13% to $0.8. The market value of their outstanding shares is at $7.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK
    $AZTR
    $BDRX
    $BTCY

    CompanyDatePrice TargetRatingAnalyst
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$40.00Hold → Buy
    Stifel
    Cogent Biosciences Inc.
    $COGT
    11/10/2025$38.00Neutral → Outperform
    Wedbush
    Cogent Biosciences Inc.
    $COGT
    10/16/2025$16.00Hold
    Stifel
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    Cogent Biosciences Inc.
    $COGT
    9/3/2025$30.00Strong Buy
    Raymond James
    Cardiff Oncology Inc.
    $CRDF
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    Cardiff Oncology Inc.
    $CRDF
    6/24/2025$3.50Hold
    Jefferies
    More analyst ratings

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the

    2/26/26 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

    MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestonesBRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.

    2/24/26 8:00:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Lindsay Brigitte Ute

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:02:04 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Interim CEO Mohindru Mani

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    2/18/26 4:01:02 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cogent Biosciences upgraded by Stifel with a new price target

    Stifel upgraded Cogent Biosciences from Hold to Buy and set a new price target of $40.00

    11/10/25 11:01:45 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cogent Biosciences upgraded by Wedbush with a new price target

    Wedbush upgraded Cogent Biosciences from Neutral to Outperform and set a new price target of $38.00

    11/10/25 10:13:55 AM ET
    $COGT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    SEC Filings

    View All

    Cardiff Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    2/25/26 8:30:30 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    2/24/26 5:09:22 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Cardiff Oncology Inc.

    10-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    2/24/26 5:07:45 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

    SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

    11/21/24 8:05:56 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ALLK
    $AZTR
    $BDRX
    $BTCY
    Financials

    Live finance-specific insights

    View All

    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the

    2/26/26 8:00:00 AM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results

    ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno

    2/11/26 4:05:00 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care